PCPei-Chi Chen

Pei-Chi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pei-Chi Chen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vitamin D3 Supplementation Enhances Symptom Relief and Modulates Microbiome and Immune Responses in Pediatric Post-Acute Sequelae of COVID-19: A Randomized Controlled Trial

    by Pei-Chi Chen, Tsunglin Liu, Yu-Ching Chuang, Yu-Lung Hsu, Yen-Hsi Chen, Chih-Yu Lin, Miao-Hsi Hsieh, Yu-Shan Ho, Xiao-Ling Liu, Wen-Shuo Kuo, et al.

    Background :Post-acute sequelae of COVID-19 (PASC) in children present persistent symptoms that impair quality of life. Vitamin D’s immunomodulatory and microbiome-modulating properties suggest its potential to alleviate PASC symptoms. This study evaluated the efficacy of Vitamin D3 supplementation in alleviating symptom severity and to explore associated immunological and microbiome alterations in children with PASC. Methods: In a double-blind randomized controlled clinical trial, 33 children with PASC were assigned to receive 2,000 IU/day of oral vitamin D (Group A, n=21) or placebo (Group B, n=12) for 6 months. Serum 25-hydroxyvitamin D [25(OH)D] levels, symptom severity (Children’s Somatic Symptom Inventory-24, CSSI-24), immune cytokines, and checkpoint proteins were assessed at baseline (M0) and 6 months (M6). Nasal and rectal microbiota were analyzed using 16S rRNA sequencing to evaluate composition and predict functional pathways. Results: Serum 25(OH)D increased significantly in Group A compared with Group B (p < 0.01). Group A demonstrated significant reductions in CSSI-24 scores (p < 0.05), with improvements in neuropsychiatric, respiratory and cardiovascular symptoms. Pro-inflammatory cytokines including IFN-γ (FDR = 0.01) and MIP-1α (FDR = 0.0004) decreased, while checkpoint proteins TIM-3 and HVEM increased (both FDR < 0.05). Nasal microbiota in Group A at M6 showed increased richness and enrichment of Sphingomonas, Paenibacillus, Ralstonia, and Sphingobium, with functional pathways related to xenobiotic metabolism altered after supplementation. Coprobacillus abundance in rectal samples positively correlated with 25(OH)D levels and negatively with IFN-γ (p = 0.02). Pooling participants from both time points across group A indicated that higher 25(OH)D levels were associated with lower symptom scores. Conclusions: Vitamin D3 supplementation improved symptom severity, modulated immune responses, and altered microbiota profiles in children with PASC. These findings support Vitamin D3 as a potential adjunctive therapy for pediatric PASC and highlight host–microbe–immune interactions as therapeutic targets.

  • Open Access

    Risk Factors and Clinical Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection in Children Previously Hospitalized for COVID-19 in Taiwan

    by Huan-Cheng Lai, Yu-Lung Hsu, Pei-Chi Chen, Yi-Fen Tsai, Chi-Hung Wei, Kai-Sheng Hsieh, Lawrence Shi-Hsin Wu, Chien-Heng Lin, Hsiao-Chuan Lin, Kao-Pin Hwang, et al.

    Background: The clinical features and risk factors of post‑acute sequelae of SARS‑CoV‑2 infection (PASC) in children remain incomplete. This study aims to clarify the manifestations and identify predictors of PASC in pediatric patients previously hospitalized for COVID‑19. Methods: We conducted this retrospective cohort study at the China Medical University Children’s Hospital in Taiwan, including 143 children aged 3-18 hospitalized for the acute COVID-19 during the Omicron pandemic from April 2022 to July 2023. PASC was assessed through phone calls, online survey, and in-person follow-ups. Data encompassing demographics, clinical presentations, laboratory results, and acute-phase treatment were collected and compared between children with and without PASC. Each child was assigned total clinical scores based on the acute-phase symptoms and treatment. We evaluated the association of the total clinical scores with PASC among study children. The receiver operating characteristic (ROC) analysis was used to determine the optimal cutoff for total clinical scores, which best differentiated occurrence of PASC. Results: Among the 143 discharged children, 35.7% (n = 51) developed PASC. Children with PASC tended to be older (mean age: 7.6 vs. 6.3 years, p = 0.05) and greater body weight (29.1 vs. 23.7 kg, p = 0.05). PASC children exhibited higher reverse transcriptase-polymerase chain reaction (RT-PCR) cycle threshold (Ct) values (17.1 vs. 14.2, p = 0.04) during the acute phase than those without PASC. There were no significant disparities in other laboratory results, length of intensive care unit (ICU) stays, bacterial coinfections, oxygen supplementation, and medication usage between two groups. Notably, compared to the control group, the total clinical scores were significantly higher in the PASC group (37.9 vs. 31.5, p = 0.02), with an optimal cutoff value of 37.7 yielding an area under the curve (AUC) of 0.70. Conclusions: This study identified a significant proportion of children developing PASC following hospitalization for acute COVID-19. Older age, greater body weight, and larger RT-PCR Ct values during the acute phase emerged as potential risk factors for developing PASC. Moreover, the clinical scoring system constructed in this study may help to predict the risk of developing PASC after discharge.

  • Open Access

    Exosomal MicroRNA let-7 Modulates Lipid Metabolism and Inflammation in Foamy Macrophages of Chronic Obstructive Pulmonary Disease

    by Miao-Hsi Hsieh, Ping-Fang Lai, Pei-Chi Chen, Xiao-Ling Liu, Wei-Leng Chen, Wen-Shuo Kuo, Shulhn-Der Wang, Hui-Fang Kao, Li-Jen Lin, Lawrence Shih-Hsin Wu, et al.

    Chronic obstructive pulmonary disease (COPD) involves persistent inflammation and dysregulated lipid metabolism, with foamy macrophages playing a central role in disease progression. Exosomes—vesicles transporting microRNAs (miRNAs)—mediate intercellular communication, but their contribution to foamy macrophage-driven COPD remains unclear. This study investigates the role of exosomal miRNAs, particularly let-7, in modulating lipid metabolism and inflammation in foamy macrophages. Bone marrow-derived macrophages (BMDMs) were treated with oxidized low-density lipoprotein (oxLDL) and lipopolysaccharide (LPS) to induce foamy macrophage formation. Exosomal miRNA profiles were analyzed, and the function of let-7c-3p was assessed via transfection. Foamy macrophages released significantly more exosomes (392.7 × 107 particles) than controls (284.9–302.5 × 107), without differences in exosome size or molecular content. The miRNA sequencing and qRT-PCR confirmed downregulation of exosomal let-7c-3p in foamy macrophages, correlating with increased RNF8 and decreased RXR expression—markers of disrupted PPAR/RXR signaling. Pathway analysis implicated let-7c-3p in regulating PPAR/RXR, WNT/β-catenin, and pulmonary fibrosis pathways. Transfection with let-7 mimics reduced lipid accumulation (52% to 19%), suppressed RNF8, restored RXR, and lowered IL-6 and TNF-α levels, indicating strong anti-inflammatory and lipid-modulating effects. Loss of exosomal let-7c-3p aggravates lipid dysregulation and inflammation in COPD by impairing PPAR/RXR signaling. Restoring let-7 expression reverses these effects, highlighting its potential as a diagnostic biomarker and therapeutic target.